Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

ZYDUSLIFE's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 1.885000
forwardPE 22.691036
debtToEquity 12.190000
earningsGrowth -0.004000
revenueGrowth 0.180000
grossMargins 0.727300
operatingMargins 0.295190
trailingEps 44.980000
forwardEps 0.000000

ZYDUSLIFE's current ratio is 1.885, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting ZYDUSLIFE has no trouble covering its short-term financial obligations.
ZYDUSLIFE's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
Zydus Lifesciences Limited's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that Zydus Lifesciences Limited is well-positioned to manage its obligations without the burden of excessive debt.
ZYDUSLIFE's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Zydus Lifesciences Limited's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of Zydus Lifesciences Limited's future.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


With analysts showing a buy bias for ZYDUSLIFE, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning ZYDUSLIFE as a safe and profitable place for investors to allocate their funds and seek growth.